ReviewInternational immunopharmacology2020
Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics.
Review in International immunopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Ocular transmission and manifestation for coronavirus disease: a systematic review.International health · 2022Pooled it
- The Impact of IgG Glycosylation in SARS-CoV-2 Infection vs. Vaccination: A Statistical Analysis.International journal of molecular sciences · 2026Article
- Eosinophils and COVID-19: Insights into immune complexity and vaccine safety.Clinical and translational allergy · 2025Review
- TLR agonists as adjuvants for viral vaccines: mechanisms, applications, and future directions.Frontiers in microbiology · 2025Review
- The Recognition Pathway of the SARS-CoV-2 Spike Receptor-Binding Domain to Human Angiotensin-Converting Enzyme 2.Molecules (Basel, Switzerland) · 2024Article
- The Role of Perceived Risk in the Relationship Between Disgust Sensitivity and COVID-19 Vaccine Hesitancy.Cognitive therapy and research · 2023Article
- Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines.Vaccines · 2023Review
- Review on the Biogenesis of Platelets in Lungs and Its Alterations in SARS-CoV-2 Infection Patients.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2023Review
- Coeliac disease in the COVID-19 pandemic: does HLA have a protective effect?Annals of medicine · 2022Article
- In silico analysis of SARS-CoV-2 spike protein N501Y and N501T mutation effects on human ACE2 binding.Journal of molecular graphics & modelling · 2022Article
- BCG and SARS-CoV-2-What Have We Learned?Vaccines · 2022Review
- Review
- Article
- SARS-CoV-2: Molecular Structure, Pathogenesis, Potential Therapeutic Targets, and Immune Response of the Infected Subject.Interdisciplinary perspectives on infectious diseases · 2022Review
- Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients.Journal of clinical and translational hepatology · 2021Review
- Antiviral Immunity in SARS-CoV-2 Infection: From Protective to Deleterious Responses.Microorganisms · 2021Review
- Neurological manifestations of coronavirus infections, before and after COVID-19: a review of animal studies.Journal of neurovirology · 2021Review
- A review and update for registered clinical studies of stem cells for non-tumorous and non-hematological diseases.Regenerative therapy · 2021Review
- COVID-19 vaccine hesitancy and related fears and anxiety.International immunopharmacology · 2021Article
- Can proteomics-based approaches further help COVID-19 prevention and therapy?Expert review of proteomics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging infectious diseases always pose a threat to humans along with plant and animal life. SARS-CoV2 is the recently emerged viral infection that originated from Wuhan city of the Republic of China in December 2019. Now, it has become a pandemic. Currently, SARS-CoV2 has infected more than 27.74 million people worldwide, and taken 901,928 human lives. It was named first 'WH 1 Human CoV' and later changed to 2019 novel CoV (2019-nCoV). Scientists have established it as a zoonotic viral disease emerged from Chinese horseshoe bats, which do not develop a severe infection. For example, Rhinolophus Chinese horseshoe bats harboring severe acute respiratory syndrome-related coronavirus (SARSr-CoV) or SARSr-Rh-BatCoV appear healthy and clear the virus within 2-4 months period. The article introduces first the concept of EIDs and some past EIDs, which have affected human life. Next section discusses mysteries regarding SARS-CoV2 origin, its evolution, and human transfer. Third section describes COVID-19 clinical symptoms and factors affecting susceptibility or resistance. The fourth section introduces the SARS-CoV2 entry in the host cell, its replication, and the establishment of productive infection. Section five describes the host's immune response associated with asymptomatic, symptomatic, mild to moderate, and severe COVID-19. The subsequent seventh and eighth sections mention the immune status in COVID-19 convalescent patients and re-emergence of COVID-19 in them. Thereafter, the eighth section describes viral strategies to hijack the host antiviral immune response and generate the "cytokine storm". The ninth section describes about transgenic humane ACE2 (hACE2) receptor expressing mice to study immunity, drugs, and vaccines. The article ends with the development of different immunomodulatory and immunotherapeutics strategies, including vaccines waiting for their approval in humans as prophylaxis or treatment measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.